Qinglong Yang

Qinglong Yang

Auto-generated profile, based on publicly available information

Qinglong Yang

Shantou University Medical College, Shantou, Guangdong, China

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 March 2026 in Nutrition Journal
Verified
Journal Article
Open access
PDF file
QYQinglong Yang
Qinglong Yang
HCHaolin Chen
Haolin Chen
NLNan Luo
Nan Luo
HLHanyuan Lin
Hanyuan Lin
HTHaoxian Tang
Haoxian Tang
QYQingtao Yang
Qingtao Yang
Benign prostatic hyperplasia (BPH) frequently affects men in middle and later life; however, the potential influence of ultra-processed food (UPF) consumpt

12 June 2026 in Cardiovascular Diabetology
Verified
Journal Article
Open access
XCXiaojing Chen
Xiaojing Chen
HTHaoxian Tang
Haoxian Tang
ZXZhuokai Xu
Zhuokai Xu
XCXueying Chen
Xueying Chen
CTCuihong Tian
Cuihong Tian
YCYequn Chen
Yequn Chen
Growth differentiation factor 15 (GDF-15) is a circulating biomarker reflecting oxidative stress, inflammation, and cellular aging. However, its role in disease risk assessment amongst individuals with cardiovascular-kidney-metabolic (CKM) syndrome stages 0-3 remains unclear. This study included 29,697 UK Biobank participants with CKM stages 0-3 defined in accordance with the American Heart Association criteria. Associations of GDF-15 with metabolic, inflammatory and liver fibrosis markers and CKM stage were examined using linear or multinomial logistic regression models. Fine-Gray competing risk regression models were used to evaluate associations with incident atherosclerotic cardiovascular disease (ASCVD), metabolic dysfunction-associated steatotic liver disease (MASLD) and their comorbidity (coexistence of both conditions). Bidirectional disease transitions were assessed using a multi-state Markov model. The relative importance of GDF-15 was evaluated using SHapley Additive exPlanations (SHAP) and likelihood ratio (LR) statistics. Improvements in risk prediction models were assessed using time-dependent area under the receiver operating characteristic curve, Brier score, integrated discrimination improvement and continuous net reclassification improvement. Amongst 29,697 participants (mean age of 56.16 years; 57.32% female), 2,786 developed ASCVD and 456 developed MASLD during follow-up. Higher GDF-15 levels were associated with poorer CKM health and showed the strongest associations with renal function markers, followed by insulin resistance indices. Each 1-unit increase in GDF-15 (normalised protein expression, log2 scale) was associated with increased risks of ASCVD (HR = 1.25, 95%CI 1.15-1.36, P = 1.35 × 10-7), MASLD (HR = 1.62, 95%CI 1.41-1.86, P = 2.06 × 10-11) and their comorbidity (HR = 1.62, 95%CI 1.32-2.18, P = 4.36 × 10-7) after multivariable adjustment for age, sex, smoking status, body mass index, diabetes mellitus, glycated haemoglobin, systolic blood pressure, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, C-reactive protein, creatinine, estimated glomerular filtration rate, urinary albumin-to-creatinine ratio, cystatin C, Townsend deprivation index, physical activity, and CKM stage. These associations remained consistent across subgroup analyses. Multi-state analyses indicated that GDF-15 predicted bidirectional progression between ASCVD and MASLD, with 10-year cumulative incidences of ASCVD and MASLD reaching 15.75% and 2.03%, respectively, among individuals in the top 10% of GDF-15 levels, and further increasing to 20.05% and 2.32% in those in the top 5%. SHAP and LR analyses showed that GDF-15 had high relative importance in predicting ASCVD and MASLD. Incorporating GDF-15 into established risk scores (PREVENT, SCORE2, FLI, FIB-4 and ARPI) showed modest improvements in risk discrimination, reclassification, and prediction error, particularly for ASCVD. In several settings, GDF-15 outperformed established biomarkers, including insulin resistance, systemic inflammation, apolipoprotein A/B, lipoprotein(a), cardiac troponin I, and N-terminal prohormone of brain natriuretic peptide. GDF-15 may serve as a promising biomarker for cardiovascular-kidney-liver-metabolic syndrome risk stratification and management.

3 September 2025 in LUTS: Lower Urinary Tract Symptoms
Verified
Journal Article
Closed access
QYQinglong Yang
Qinglong Yang
HCHaolin Chen
Haolin Chen
HLHanyuan Lin
Hanyuan Lin
HTHaoxian Tang
Haoxian Tang
NLNan Luo
Nan Luo
QYQingtao Yang
Qingtao Yang

1 January 2026 in The World Journal of Men's Health
Verified
Journal Article
Open access
QYQinglong Yang
Qinglong Yang
HCHaolin Chen
Haolin Chen
ZLZexuan Liu
Zexuan Liu
GHGaoming Hou
Gaoming Hou
WLWenqiang Liao
Wenqiang Liao
QYQingtao Yang
Qingtao Yang
Benign prostatic hyperplasia (BPH) and rheumatoid arthritis (RA) have both been associated with inflammatory processes; however, their association remains unclear. This study explored the prospective association between BPH and the subsequent risk of RA using data from the UK Biobank, and further evaluated whether the systemic immune-inflammation index (SII) and the neutrophil-to-lymphocyte ratio (NLR) are associated with this relationship. A total of 222,891 males without RA or prostate cancer at baseline were included. BPH was identified through self-report, hospital ICD-10 codes (N40), and primary care records. Incident RA was defined using hospital ICD-10 codes (M05 to M06). Multivariable Cox proportional hazards models were applied to assess the association between BPH and risk of incident RA. Mediation analyses were used to explore the potential role of SII and NLR in this association. Sensitivity analyses, including subgroup analyses, multiple imputation, exclusion of early RA cases, and competing risk models, were performed to test robustness. During a median follow-up of 14 years, 2,252 incident RA cases were documented. After multivariable adjustment, BPH was associated with a higher risk of RA (hazard ratio=1.19, 95% confidence interval: 1.03 to 1.37). The association remained consistent across sensitivity analyses. Mediation analyses suggested that SII and NLR may partly account for the observed association between BPH and RA (4.28% and 7.25%, respectively). BPH was associated with an increased risk of RA, and systemic inflammatory markers were also associated with this relationship.